{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-320153","form_type":"8-K/A","ticker":"RVTY","cik":"0000031791","company_name":"REVVITY, INC.","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.057676+00:00","generated_at":"2026-06-28T13:22:42.218970+00:00","sec_items":["2.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioLegend FY2020 audited: revenue $241.9M, net income $90.6M","bullets":["BioLegend net sales $241.9M, gross profit $169.7M, operating income $109.6M, net income $90.2M.","Total assets $465.9M at Dec 31, 2020; cash $134.4M, short-term investments $90.0M.","Pro forma combined financials for PerkinElmer and BioLegend for FY2020 and H1 2021 filed.","Acquisition completed Sept 17, 2021 via merger of wholly owned subsidiaries."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-320153","json":"https://secwatch.observer/filing/0001193125-21-320153.json","markdown":"https://secwatch.observer/filing/0001193125-21-320153.md","text":"https://secwatch.observer/filing/0001193125-21-320153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/31791/000119312521320153/0001193125-21-320153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/31791/000119312521320153/d169075d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:22:42.218970+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}